

FORM 7
MONTHLY PROGRESS REPORT
For the Month of December, 2017

Name of CSE Issuer: **Healthspace Data Systems Ltd. (the “*Issuer*”).**

Trading Symbol: **HS**

Number of Outstanding Listed Securities: **125,987,988 common shares**

Date of filing: **January 2, 2018**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

HealthSpace is now delivering its new Software-as-a-Service (SaaS) flagship technology platform HS Cloud Suite Pro, which incorporates a cloud-enabled administration dashboard; with a multi-endpoint mobile auditing and reporting system that offers native apps on all major platforms; and a rich reporting and analytics toolset to maximize business intelligence activities. Feedback on this new platform from existing customers and new prospective clients in both government and commercial enterprise engagements has been very positive.

HealthSpace’s ongoing engagement with government customers in both the US and Canada continues to drive growth and viable learning opportunities to continue to innovate our technology offerings. In 2017, we are now actively introducing our platform and services into commercial enterprise clients in food & beverage, hospitality, assisted living, and child-care. Ongoing discovery work based on HealthSpace’s agricultural capabilities is now being integrated into cannabis production and distribution processes through work with both US and Canadian partners.

2. Provide a general overview and discussion of the activities of management.

Please see item 1

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Please see description above.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On December 6, 2017 the Company announced that it signed a Letter of Intent (LOI) to collaborate with SIMBA Chain Inc. of Plymouth, Indiana to expand HealthSpace's ability to develop blockchain technology into its existing platform. SIMBA Chain will use its expertise and experience in blockchain to help develop and guide the initial prototype HealthSpace will produce. SIMBA Chain will also assist in the development of a white-paper for how HealthSpace can leverage blockchain into both the public and private sectors for auditing purposes.

HealthSpace intends to use the initial version developed with SIMBA Chain ("SIMBA") to provide a proof of concept in order to demonstrate how audits and other regulatory checklists can be stored efficiently and cohesively in the blockchain. By doing so, HealthSpace can further integrate its existing iPad and Android apps to go beyond just government inspections and into private audits. Combining audit control software with the power of the blockchain will create a comprehensive toolset for furthering transparency between multiple parties who need concurrent access to the same chain of data, but have different rules for how or when that data is entered.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

None.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

The Issuer is working with its legal counsel on the claim and counterclaim filed in November 2016.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

- **On December 7, 2017 the Company announced that it closed its previously announced private placement for gross proceeds of \$1,060,000. As mentioned in the Company's December 5, 2017 news release, Vanbex Capital, sister company of Vanbex Group was issued 10,000,000 shares of the Company at a price of \$0.10 per share. An additional 600,000 shares were also issued for a total issuance of 10,600,000 shares.**

- **On December 15, 2017 the Company announced that it granted stock options and restricted stock units to directors, officers, employees and consultants of the Company. The stock options granted allow the optionees the ability to purchase a total of 2,375,000 common shares of the company at an exercise price of \$0.15 cents per share for a five-year term. The restricted stock units granted allow the recipients the ability to purchase a total of 1,100,000 common shares of the Company for a five-year term.**

- **A total of 2,974,300 shares were issued pursuant to exercise of debentures, exercise of stock options, an asset purchase agreement and exercise of RSU's.**

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: January 2, 2018

Zula Kropivnitski
Name of Director or Senior
Officer

"Zula Kropivnitski"
Signature

Chief Financial Officer
Official Capacity

<i>Issuer Details</i>		
Name of Issuer Healthspace Data Systems Ltd.	For Month End December, 2017	Date of Report YY/MM/DD 2018/01/02
Issuer Address 201 7491 Vedder Road		
City/Province/Postal Code Chilliwack, BC V2R 6E7	Issuer Fax No. ()	Issuer Telephone No. 1-866-860-4224